Bristol-Myers to file for OTC sale of its Pravachol statin

12/13/2004 | Wall Street Journal, The

Bristol-Myers Squibb has taken official action to get FDA approval to sell its cholesterol-lowering Pravachol over the counter, possibly paving the way for OTC versions of other statins. Bristol-Myers faces the loss of its patent on Pravachol in just over a year and OTC sales are seen as opening a new market for the drugs. An FDA advisory panel plans to meet in mid-January on a similar request by Merck for Mevacor.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX